Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian F. Sullivan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 155
- Beta
- 0.16
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 1.79
Financials
Net Income
$-78.86MEBITDA
$-54.64MFree Cash Flow
$-55.48MEPS (diluted)
$-1.44Shares Outstanding (diluted)
54.82M+716.0%Operating Expenses
$66.12MCash & Debt
$754.04MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-177.04M | $-3.78 |
| 2024 | $0.00 | $-111.78M | $-2.83 |
| 2023 | $0.00 | $-63.78M | $-2.69 |
| 2022 | $0.00 | $-40.37M | $-2.68 |
| 2021 | $0.00 | $-29.61M | $-2.28 |
| 2020 | $0.00 | $-9.47M | $-0.89 |
| 2019 | $0.00 | $-7.36M | $-0.69 |
| 2018 | $0.00 | $-7.48M | $-0.74 |
| 2017 | $0.00 | $-6.25M | $-0.84 |
| 2016 | $0.00 | $-3.31M | $-0.49 |
| 2015 | $0.00 | $-2.26M | $-0.36 |
Valuation
CELChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-68.75%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·4d ago·Neutral
Celcuity Appoints David Gryska To Its Board Of Directors Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board
View source ↗ - Newsfool.com·5d ago·Positive
Why Celcuity Stock Was a Winner on Wednesday This is a breast cancer treatment, Revtorpyk. It was approved by the FDA in July.
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
…ykhcp.com to access a comprehensive patient support program through REVTORPYK Support Services MINNEAPOLIS, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that REVTORPYK™ (gedatolisib) is now commercially available in the United States for eligible patients with hormone receptor-positive (“HR+”), human epidermal growth facto…
View source ↗ - Newsseekingalpha.com·26d ago·Neutral
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Celcuity To Participate in Upcoming Investor Conferences MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
View source ↗ - News (RSS)yahoo·39d ago·Neutral
Celcuity (CELC): Landmark Approval Collides With A Costly Launch
View source ↗ - Newsglobenewswire.com·41d ago·Negative
…TORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone re…
View source ↗ - Newsseekingalpha.com·53d ago·Positive
… Commercial Story Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial investment, with SG&A surging for launch, but a strengthened $754M cash position provides funding visibility into 2029. VIKTORIA-1 data show REVTORPYK delivers a step-change in efficacy and tolerability, supporting rapid physician adoption and a potential blockbuster franchise.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Neutral
Celcuity Q2 Earnings Call Highlights Celcuity NASDAQ: CELC said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026 following its recent FDA approval.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-1.45 per share
Typical surprise +6.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.44 vs $-1.16miss
- Thu, May 14$-0.97 vs $-1.04beat
- Wed, Mar 25$-0.97 vs $-1.06beat
- Wed, Nov 12$-0.92 vs $-1.02beat
- Thu, Aug 14$-1.04 vs $-0.90miss
- Wed, May 14$-0.86 vs $-0.95beat
Estimates and results for CELC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CELC officers and directors.
- Bought
- $9.6m
- Sold
- $332.4m
4 trades
24 trades
- Baker Bros. Advisors Lpsold
- Baker Bros. Advisors Lpsold
- Dalvey Davidsold
- Buller Richard Esold
- Buller Richard Esold
- Buller Richard Esold
- Buller Richard Esold
- Buller Richard Esold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Tom Malinowskihouse · NJ07 · disclosed Jun 23, 2021 (28d later)Sell$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (260d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.